The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Mitoxantrone, More than Just Another Topoisomerase II Poison
Abstract
Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is firmly established as a DNA topoisomerase II poison within mammalian cells, it is now clear that the drug interacts with a much broader range of biological macromolecules both covalently and noncovalently. Here, we consider each of these interactions in the context of their wider biological relevance to cancer therapy and highlight how they may be exploited to further enhance the therapeutic value of mitoxantrone. In doing so, it is now clear that mitoxantrone is more than just another topoisomerase II poison.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel
Symes, J. C., Kurin, M., Fleshner, N. E., & Medin, J. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0335 · Cited by 24
RUBIDOMYCIN: A NEW ANTIBIOTIC WITH CYTOSTATIC PROPERTIES.
Dubost, M., Ganter, P., Maral, R., NINET, L., Pinnert, S., Preud'homme, J., & Werner, G. H. (1964) · PubMed · Cited by 23
Identification of Potential Small Molecule Binding Pockets on Rho Family GTPases
Ortiz‐Sánchez, J. M., Nichols, S. E., Sayyah, J., Brown, J. H., McCammon, J. A., & Grant, B. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040809 · Cited by 22
Seifrtová, M., Havelek, R., Soukup, T., Filipová, A., Mokrý, J., & Rezacova, M. (2013) · PubMed · Cited by 21
Taylor, J. A., Mitchenall, L. A., Rejzek, M., Field, R. A., & Maxwell, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058010 · Cited by 19
A novel small-molecule screening strategy identifies mitoxantrone as a RhoGTPase inhibitor
Bidaud-Meynard, A., Arma, D., Taouji, S., Laguerre, M. S., Dessolin, J., Rosenbaum, J., Chevet, É., & Moreau, V. (2012) · Biochemical Journal · doi:10.1042/bj20120572 · Cited by 17
DNA double-strand break repair in two radiation-sensitive mouse mammary carcinoma cell lines
Warters, R. L., Barrows, L. R., & Chen, D. J. (1995) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(94)00036-6 · Cited by 14
Evison, B. J., Pastuovic, M., Bilardi, R. A., Forrest, R. A., Pumuye, P. P., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.013 · Cited by 12
Self-citationInhibition of c-Abl Kinase Activity Renders Cancer Cells Highly Sensitive to Mitoxantrone
Alpay, K., Farshchian, M., Tuomela, J. M., Sandholm, J. A., Aittokallio, K., Siljamäki, E., Kallio, M. J., Kähäri, V., & Hietanen, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105526 · Cited by 9
Cited by
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Guan, Y., Jiang, S., Ye, W., Ren, X., Wang, X., Zhang, Y., Yin, M., Wang, K., Tao, Y., Yang, J., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03153-x · Cited by 34
Metadata
- Authors
- Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2015-08-19
- Volume
- 36
- Issue
- 2
- Pages
- 248-299
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1929164375
- Cited by
- 253
- References
- 209
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.